Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 19/20 | 1.00 |
| ▸ | GSK3B | P49841 | 19/20 | 1.00 |
| ▸ | CDK1 | P06493 | 18/20 | 1.00 |
| ▸ | MAPK8 | P45983 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | AURKA | O14965 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | PAK4 | O96013 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | RET | P07949 | 2/20 | 1.00 |
| ▸ | KDR | P35968 | 2/20 | 1.00 |
| ▸ | CDK8 | P49336 | 2/20 | 1.00 |
| ▸ | ACVR1 | Q04771 | 2/20 | 1.00 |
| ▸ | PTK2 | Q05397 | 2/20 | 1.00 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 1.00 |
| ▸ | ALK | Q9UM73 | 2/20 | 1.00 |
| ▸ | CDC7 | O00311 | 1/20 | 1.00 |
| ▸ | PLK4 | O00444 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12205754 | 0.90 | GSK3A (0.82) | GSK3AGSK3BCDK1MAPK8CDK2 | |
| SCHEMBL27824304 | 0.84 | GSK3A (0.72) | GSK3AGSK3BCDK1MAPK8CDK2 | |
| SCHEMBL13502526 | 0.81 | GSK3A (1.00) | GSK3AGSK3BCDK1MAPK8CDK2 | |
| SCHEMBL1778374 | 0.79 | GSK3A (0.65) | GSK3AGSK3BCDK1MAPK8CDK2 | |
| SCHEMBL3580619 | 0.77 | GSK3A (0.63) | GSK3AGSK3BCDK1MAPK8CDK2 | |
| SCHEMBL3587782 | 0.77 | GSK3A (0.66) | GSK3AGSK3BCDK1MAPK8CDK2 | |
| SCHEMBL1778992 | 0.76 | GSK3A (0.62) | GSK3AGSK3BCDK1MAPK8CDK2 | |
| SCHEMBL3100624 | 0.75 | GSK3A (0.70) | GSK3AGSK3BCDK1MAPK8CDK2 | |
| Iodide SCHEMBL5618949 | 0.75 | GSK3A (0.60) | GSK3AGSK3BCDK1MAPK8CDK2 | |
| SCHEMBL1778404 | 0.75 | GSK3A (0.59) | GSK3AGSK3BCDK1MAPK8CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102316868-A | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI AVENTIS | 2012-01-11 | — | — | CN | claimed |
| EP-2370077-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI (FR) | 2011-10-05 | — | — | EP | claimed |
| WO-2010080563-A2 | METHOD FOR TREATING MACULAR DEGENERATION | SANOFI-AVENTIS (FR) | 2010-07-15 | — | — | WO | claimed |
| US-20140142110-A1 | KINASE INHIBITOR | SANOFI (FR) | 2014-05-22 | — | — | US | disclosed |
| US-20140142110-A1 | KINASE INHIBITOR | SANOFI (FR) | 2014-05-22 | — | — | US | disclosed |
| US-20140142110-A1 | KINASE INHIBITOR | SANOFI (FR) | 2014-05-22 | — | — | US | disclosed |
| US-8658649-B2 | Kinase inhibitor | SANOFI (FR) | 2014-02-25 | — | — | US | disclosed |
| US-8658649-B2 | Kinase inhibitor | SANOFI (FR) | 2014-02-25 | — | — | US | disclosed |
| US-8658649-B2 | Kinase inhibitor | SANOFI (FR) | 2014-02-25 | — | — | US | disclosed |
| EP-2653193-A1 | Method for treating macular degeneration | SANOFI (FR) | 2013-10-23 | — | — | EP | disclosed |
| EP-2653193-A1 | Method for treating macular degeneration | SANOFI (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-20100035884-A1 | KINASE INHIBITOR | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100035884-A1 | KINASE INHIBITOR | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-20100035884-A1 | KINASE INHIBITOR | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| WO-2009114373-A1 | TREATMENT FOR OCULAR-RELATED DISORDERS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| WO-2009114373-A1 | TREATMENT FOR OCULAR-RELATED DISORDERS | SANOFI-AVENTIS (FR) | 2009-09-17 | — | — | WO | disclosed |
| EP-2094708-A2 | A PYRROLOPYRAZIN AS SYK-KINASE INHIBITOR | Sanofi-Aventis (FR) | 2009-09-02 | — | — | EP | disclosed |
| CN-101511838-A | Pyrrolopyrazines as SYK-kinase inhibitors | SANOFI AVENTIS (FR) | 2009-08-19 | — | — | CN | disclosed |
| WO-2008033798-A2 | A PYRROLOPYRAZIN AS SYK-KINASE INHIBITOR | SANOFI-AVENTIS (FR) | 2008-03-20 | — | — | WO | disclosed |
| WO-2008033798-A2 | A PYRROLOPYRAZIN AS SYK-KINASE INHIBITOR | SANOFI-AVENTIS (FR) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035884-A1 | KINASE INHIBITOR | MAP3K1, MAP3K20, MAP3K19 | GSK3A 276/4885GSK3B 266/4885CDK1 37/4885 |
| US-20140142110-A1 | KINASE INHIBITOR | MAP3K1, MAP3K20, MAP3K19 | GSK3A 276/4885GSK3B 266/4885CDK1 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.